Rhythm Pharma Initiates First Human Dosing in Early-Stage Study of RM-718, a Once-Weekly Compound Targeting MC4R Receptors.

Terbinafine, a small but powerful drug, works by blocking SQLE, a key enzyme in making ergosterol, which is essential for fungal cell membranes.

US FDA grants Bio-Thera Solutions approval to start Phase II trial of BAT8006, a novel ADC aimed at Folate Receptor alpha.

Active Pharmaceutical Ingredient (API) refers to the main substance in a drug that provides the therapeutic effect.

AbbVie Plans to Take Over Landos Biopharma, Enhancing Its Collection of Treatments for Inflammation and Autoimmunity.

Nystatin, a minuscule molecule drug with a penchant for functioning as an ergosterol binder, engages in targeting fungal cells, blocking their growth and replication.

Ferrer and Verge Genomics have entered into a collaboration to jointly advance the experimental treatment for ALS, designated as VRG50635, into clinical trials.

Phagocytosis is an essential immune response where phagocytes consume foreign particles, dead cells, and pathogens like bacteria and viruses.

Astria Therapeutics Reveals Encouraging Early Findings in ALPHA-STAR Phase 1b/2 Study for HAE with STAR-0215.

Carbamazepine, a minuscule molecule drug, exerts its therapeutic effect through the blocking of sodium channels in the human body.

Ultomiris receives US green light to treat adult patients with spectrum disorder related to neuromyelitis optica (NMOSD).

This article introduces the new drugs related to GPCR that were approved by the FDA in 2023.